Main Article Content
cholesterol and alcohol by coacervation phase separation method to overcome the bioavailability problem of this potential
biologically active compound. The formulated system was characterized for size, drug entrapment, inâ€‘vitro drug release studies and inâ€‘vivo antiâ€‘inflammatory effect through animal model. Inâ€‘vitro release data of ursolic acid from proniosomal gel revealed a time dependent near linear relationship. Entrapment efficiency of the formulated gel was found > 90% and total % cumulative release of ursolic acid satisfactory as 60.8% after 24 h. Release pattern was also found almost constant. Inâ€‘vivo evaluation revealed that the developed formulation exhibited significant antiâ€‘inflammatory value (P < 0.05) in carrageenan induced rat paw edema model and was found quite comparable with the standard diclofenac gel (voveran gel) in terms of % inhibition of edema.
Key words: Nonâ€‘steroidal antiâ€‘inflammatory drugs, proniosomes, topical drug delivery, ursolic acid
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Kim KA, Lee JS, Park HJ, Kim JW, Kim CJ, Shim IS, et al. Inhibition of
cytochrome P450 activities by oleanolic acid and ursolic acid in human
liver microsomes. Life Sci 2004;74:2769â€‘79.
Baricevic D, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A,
et al. Topical antiâ€‘inflammatory activity of Salvia officinalis L. leaves: The
relevance of ursolic acid. J Ethnopharmacol 2001;75:125â€‘32.
Vasconcelos MA, Royo VA, Ferreira DS, Crotti AE, Andrade e Silva ML,
Carvalho JC, et al. In vivo analgesic and antiâ€‘inflammatory activities of
ursolic acid and oleanoic acid from Miconia albicans (Melastomataceae).
Z Naturforsch C 2006;61:477â€‘82.
Pandey G. Some important anticancer herbs: a review. Int Res J Pharm
Parfentâ€™eva EP. Effect of ursolic acid and its derivatives on lipid
metabolism in experimental atherosclerosis. Chem Abstr 1979;9:9279.
Shai LJ, McGaw LJ, Aderogba MA, Mdee LK, Eloff JN. Four
pentacyclic triterpenoids with antifungal and antibacterial activity
from Curtisia dentata (Burm.f) C.A. Sm. leaves. J Ethnopharmacol
Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol
Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane
group as tools in cancer therapy. Planta Med 2009;75:1549â€‘60.
Nair B, Taylorâ€‘Gjevre R. A review of topical diclofenac use in
musculoskeleton disease. Pharmaceuticals 2010;3:1892â€‘908.
Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis
Res Ther 2013;15 Suppl 3:S2.
Li Y, Xing D, Chen Q, Chen WR. Enhancement of chemotherapeutic
agentâ€‘induced apoptosis by inhibition of NFâ€‘kappaB using ursolic acid.
Int J Cancer 2010;127:462â€‘73.
Huang HC, Huang CY, Linâ€‘Shiau SY, Lin JK. Ursolic acid inhibits ILâ€‘1beta
or TNFâ€‘alphaâ€‘induced C6 glioma invasion through suppressing the
association ZIP/p62 with PKCâ€‘zeta and downregulating the MMPâ€‘9
expression. Mol Carcinog 2009;48:517â€‘31.
Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B,
et al. Natural products as a gold mine for arthritis treatment. Curr Opin
Ringbom T, Segura L, Noreen Y, Perera P, Bohlin L. Ursolic acid from
Plantago major, a selective inhibitor of cyclooxygenaseâ€‘2 catalyzed
prostaglandin biosynthesis. J Nat Prod 1998;61:1212â€‘5.
Manikrao AM, Khatale PN, Jawarkar RD, Vyas JV, Mahajan DT, Masand VH,
et al. Presuming the probable antiâ€‘inflammatory mechanism of ursolic
acid: A plant derived pentacyclic triterpenoid, using molecular docking.
Scholar Res Libr 2011;1:9â€‘13.
Blazekâ€‘Welsh AI, Rhodes DG. Maltodextrinâ€‘based proniosomes. AAPS
Pharm Sci 2001;3:E1.
Bairwa NK, Choudhary D. Proniosome: A review. Asian J Biochem Pharm
Goyal C, Ahuja M, Sharma SK. Preparation and evaluation of
antiâ€‘inflammatory activity of gugulipidâ€‘loaded proniosomal gel. Acta
Pol Pharm 2011;68:147â€‘50.
Niemiec SM, Ramachandran C, Weiner N. Influence of nonionic
liposomal composition on topical delivery of peptide drugs into
pilosebaceous units: An in vivo study using the hamster ear model.
Pharm Res 1995;12:1184â€‘8.
Arunothayanun P, Bernard MS, Craig DQ, Uchegbu IF, Florence AT. The
effect of processing variables on the physical characteristics of nonâ€‘ionic
surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether.
Int J Pharm 2000;201:7â€‘14.
Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery
of levonorgestrel for effective contraception. J Control Release
Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. In vitro skin permeation of estradiol
from various proniosome formulations. Int J Pharm 2001;215:91â€‘9.
Hu C, Rhodes DG. Proniosomes: A novel drug carrier preparation. Int
J Pharm 1999;185:23â€‘35.
Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A. Ursolic acid
in cancer prevention and treatment: Molecular targets, pharmacokinetics
and clinical studies. Biochem Pharmacol 2013;85:1579â€‘87.
Alam MI, Baboota S, Kohli K, Ali J, Ahuja A. Pharmacodynamic evaluation
of proniosomal transdermal therapeutic gel containing celecoxib. Sci
Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug
carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm
Yoshioka T, Sternberg B, Florence AT. Preparation and properties of
vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80)
and a sorbitan triester (Span 85). Int J Pharm 1994;105:1â€‘6.
Bhaskaran S, Panigarhi L. Formulation and evaluation of niosomes using
different nonâ€‘ionic surfactants. Indian J Pharm Sci 2002;64:63â€‘5.